Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
for Relapsing Multiple Sclerosis
Drug: Remibrutinib
38 locations incl. Scottsdale
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 40 - 70
Code: NCT06846281·Phase 3·Recruiting